Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on August 18, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Positive topline LUCIDITY Phase 3 results for avexitide in post-bariatric hypoglycemia.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Positive topline LUCIDITY Phase 3 results for avexitide in post-bariatric hypoglycemia
- Target population: patients following Roux-en-Y gastric bypass surgery
- Clinical-stage catalyst potentially advancing avexitide toward regulatory review
- Investor presentation slides attached as Exhibit 99.1 for efficacy and safety details
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 LUCIDITY met primary and all secondary endpoints, materially advancing avexitide toward potential FDA approval
- Avexitide reduced composite Level 2/3 hypoglycemic events 55% versus placebo, with rate ratio 0.45 and p=0.000003
- Generally favorable safety profile, with no treatment-related serious adverse events and mostly mild or moderate events
- NDA submission anticipated by end of 2026, with potential commercial launch in 2027 if approved
- Approximately 160,000 U.S. people living with PBH represent a sizable unmet-need market with no approved treatment options
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.